Company Overview
Vistagen Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapies designed to address neuropsychiatric and neurological disorders. The company functions within the Healthcare sector and specifically within the Biotechnology industry, an environment characterized by high research and development expenditures and significant regulatory scrutiny before products reach the market. The firm maintains a market capitalization of $22.56M and employs a workforce of 59 individuals, generating an annual revenue of $789,000 based on trailing twelve-month data. These financial figures indicate that the company is a small-cap entity with limited revenue generation relative to its market valuation, suggesting a position typical of early-stage biotechnology firms that prioritize pipeline advancement over immediate profitability.
Financial Health
The company reported a revenue of $789,000 over the trailing twelve months, while the net income stood at -$67,046,000 and EBITDA was -$69,717,000. The substantial gap between the minimal revenue and the significant net loss reveals a cost structure dominated by high operating expenses, likely driven by research and development activities necessary for advancing a clinical-stage product pipeline. Free cash flow was recorded at -$36,167,000, indicating that the company is currently burning cash to fund its operations and development efforts rather than generating liquidity from its core business. Despite these outflows, the company holds $61.77M in cash against $1.43M in debt, resulting in a debt-to-equity ratio of 2.80. The current ratio is 4.67, which indicates a strong position regarding short-term liquidity as the firm possesses ample current assets to cover its short-term obligations. Return on Equity is -101.6% and Return on Assets is -55.5%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate negative returns, a common characteristic for clinical-stage biotechs before product approval. The profit margin is 0.0%, reflecting the absence of profitability in the current period, while the gross margin stands at 100.0%, suggesting that cost of goods sold is negligible relative to revenue, though this does not offset the high operating expenses captured in the operating margin of -6450.8%.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, whereas the forward P/E is listed as -0.50, implying that the market is pricing the stock based on future expectations that differ significantly from current loss-making operations. The price-to-book ratio is 0.44, which indicates that the market is valuing the company at less than its book value, suggesting a premium is not being assigned over the tangible assets held by the entity. Alternative valuation metrics such as the price-to-sales ratio of 28.59 and an EV/EBITDA of 0.54 suggest that investors are placing a high multiple on the company's revenue stream despite the lack of earnings, reflecting the potential value of the underlying intellectual property and pipeline. The 52-week high is $5.14 and the 52-week low is $0.43, meaning the current price sits within a wide trading range that reflects high volatility typical of small-cap biotechnology stocks. The beta value is 0.33, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting that the stock is less sensitive to general market movements compared to large-cap equities.
Growth & Income
Revenue growth year-over-year is 29.5%, while earnings growth is N/A due to the company's continued losses, implying that top-line expansion is occurring without a corresponding improvement in the bottom line at this stage of development. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available resources back into its research and development pipeline rather than distributing income to shareholders. This approach is typical for clinical-stage biopharmaceutical companies that require capital to progress their investigational products through Phase III clinical trials before generating commercial revenue. The overall growth and income profile is defined by strong top-line revenue expansion coupled with negative earnings and no dividend distribution, highlighting a capital-intensive growth strategy focused on long-term product potential rather than short-term financial returns.